GAM
IRWD icon

Gemmer Asset Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Gemmer Asset Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3
Closed – – 1393
2019
Q3 		$0 Buy
+3
New +$29 ﹤0.01% 1430

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gemmer Asset Management's IRWD Position: Q4 2019 in Review

Gemmer Asset Management sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2019, closing a stake of 3 shares.

Gemmer Asset Management first reported a position in IRWD in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 195 funds tracked by Wall St. Rank hold IRWD as of Q4 2019.

  • Gemmer Asset Management reported no remaining Ironwood Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Gemmer Asset Management sold 3 Ironwood Pharmaceuticals shares in Q4 2019.
  • Gemmer Asset Management first reported a position in Ironwood Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Gemmer Asset Management's Ironwood Pharmaceuticals position peaked at $0 in Q3 2019.
  • 195 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2019.

Based on Gemmer Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.